Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) is a clinical-stage biopharmaceutical company dedicated to improving patient outcomes through the development of best-in-class therapies for liver and viral diseases. Founded in 2018 and headquartered in South San Francisco, California, Aligos leverages its deep expertise in drug development to address high unmet medical needs in areas such as chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
Core Focus and Therapeutic Pipeline
Aligos is at the forefront of innovation in the biopharmaceutical industry, with a robust pipeline of therapeutics designed to tackle some of the most challenging diseases. Its lead candidates include:
- ALG-000184: A capsid assembly modulator (CAM-E) targeting CHB, designed to disrupt multiple stages of the hepatitis B virus lifecycle for sustained viral suppression.
- ALG-055009: A thyroid hormone receptor beta (THR-β) agonist for MASH, showing significant reductions in liver fat and promising cardiovascular benefits in clinical trials.
- ALG-097558: A pan-coronavirus protease inhibitor with potential applications in current and future pandemics.
These candidates reflect Aligos' commitment to addressing diseases with limited treatment options, leveraging advanced molecular design and pharmacokinetics to achieve superior efficacy and tolerability.
Industry Context and Market Position
The biopharmaceutical landscape for liver and viral diseases is characterized by significant unmet needs. CHB affects over 290 million individuals globally, while MASH prevalence is projected to rise sharply due to lifestyle-related factors. Aligos positions itself as a key player in these markets by focusing on innovative, science-driven solutions that aim to outperform existing therapies in efficacy, safety, and patient adherence.
Strategic Collaborations and Differentiation
Aligos collaborates with industry leaders, such as Xiamen Amoytop Biotech, to accelerate the clinical development of its drug candidates. Its differentiation lies in its purpose-built pipeline, deep R&D expertise, and a strategic focus on best-in-class therapeutics. By addressing both viral replication and immune modulation, Aligos aims to redefine treatment paradigms for CHB and MASH.
Future Outlook
With a clear regulatory pathway and ongoing clinical advancements, Aligos is well-positioned to bring transformative therapies to market. Its financial strategy, supported by private placements and partnerships, ensures the sustainability of its operations through key developmental milestones. Aligos' commitment to innovation and patient-centric solutions underscores its potential to make a significant impact in the biopharmaceutical industry.
Aligos Therapeutics (NASDAQ: ALGS) reported strong financial results for Q4 and the full year 2020, with cash reserves of $243.5 million following a successful IPO raising $167.2 million. The company advanced two drug candidates, ALG-010133 and ALG-000184, into clinical trials for Chronic Hepatitis B (CHB) and expects to generate safety and antiviral activity data in 2021. However, net losses reached $108.5 million for the year, up from $52.3 million in 2019, reflecting increased R&D expenses of $79.9 million.
Aligos Therapeutics (Nasdaq: ALGS) has initiated dosing of its first drug candidate, ALG-010133, in chronic hepatitis B (CHB) patients as part of the ALG-010133-101 study. This proprietary molecule aims to reduce viral S-antigen levels, pivotal for HBV replication. Preclinical studies show promising inhibition of S-antigen. Currently, 72 healthy volunteers have been dosed, indicating an acceptable safety profile. Results from the initial patient cohorts are expected in the second half of 2021. Aligos aims to develop a treatment regimen that may lead to a functional cure for CHB.
Aligos Therapeutics (Nasdaq: ALGS) announced the presentation of its SARS-CoV-2 3CLpro inhibitor candidate, ALG-097111, at the 28th Conference on Retroviruses and Opportunistic Infections. The presentation highlighted in vivo evidence of potent virus inhibition in infected hamsters, achieving a 3.5 log10 reduction in viral RNA. ALG-097111 showed high selectivity with an IC50 of 7 nM, indicating its potential as a targeted therapeutic option amid COVID-19's evolving strains. CEO Lawrence Blatt emphasized its importance for untreated and vaccine-resistant patients.
Aligos Therapeutics (Nasdaq: ALGS) will present four posters at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL) from February 4-6, 2021. The presentations will showcase progress in their chronic hepatitis B (CHB) drug candidates, ALG-010133 and ALG-000184, currently in Phase 1a/b studies. Notable findings include ALG-010133's promising preclinical efficacy and pharmacokinetics, and ALG-000184's safety and tolerability data. These trials aim to develop effective combination therapies against CHB.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that CEO Lawrence Blatt will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 PM ET. The presentation will include a virtual Q&A session, with the webcast recording available for 30 days afterward. Aligos focuses on developing novel therapeutics for viral infections and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis. Founded in 2018, the company aims to lead in antiviral therapies using its extensive drug development expertise.
Aligos Therapeutics (Nasdaq: ALGS) recently presented at the RespiDART & Emerging Viruses 2020 meeting, showcasing advancements in their SARS-CoV-2 therapeutic candidate, ALG-097111. The presentation underscored the development of a multiplex screening platform to identify selective inhibitors for the viral 3CLpro protease, essential for viral replication. ALG-097111 demonstrated significant inhibition without affecting human cathepsin L, highlighting its potential as a targeted treatment for SARS-CoV-2. Collaborations with KU Leuven were pivotal in these developments.
Aligos Therapeutics (Nasdaq: ALGS) announced a collaboration with Merck to leverage its oligonucleotide platform technology for developing therapies targeting non-alcoholic steatohepatitis (NASH) and potentially other conditions. The agreement includes an upfront payment and up to $458M in development milestones along with tiered royalties on sales. Aligos will focus on designing and optimizing oligonucleotides, while Merck will handle clinical development and commercialization. This collaboration aims to address the critical need for effective NASH treatments amidst growing liver disease concerns.
Aligos Therapeutics (Nasdaq: ALGS) presented six posters and one oral presentation at the AASLD Liver Meeting Digital Experience 2020, highlighting advancements in its liver disease programs. Key updates included progress on chronic hepatitis B (CHB) therapies and the nonalcoholic steatohepatitis (NASH) treatment candidate ALG-055009. The company is optimistic about its combination regimens for CHB that may lead to functional cures and has begun Phase 1 trials for two drug candidates, ALG-010133 and ALG-000184, aimed at CHB.
Aligos Therapeutics (Nasdaq: ALGS) announced participation in two virtual investor conferences: the Jefferies 2020 Virtual London Healthcare Conference from November 17-19, and the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3. Management will present at both events and will be available for one-on-one meetings. Aligos focuses on developing novel therapeutics for viral infections and liver diseases, aiming to advance targeted antiviral therapies.
Aligos Therapeutics (Nasdaq: ALGS) has announced that its Belgian subsidiary, Aligos Belgium BV, received a €1.8M grant from the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project on combination therapy for Chronic Hepatitis B (CHB). This three-year project, named CoHeBA, aims to explore the therapeutic candidates' mechanisms and involves collaborations with leading laboratories globally. Aligos CEO Lawrence Blatt expressed optimism that project outcomes will enhance their therapeutic developments for CHB, which affects over 290 million people worldwide.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
What does Aligos Therapeutics specialize in?
What are Aligos' lead drug candidates?
How does Aligos differentiate itself in the biopharmaceutical industry?
What collaborations has Aligos entered into?
What challenges does Aligos face in its market?
What is the market potential for Aligos' therapies?
What is ALG-000184 and how does it work?
What progress has Aligos made in clinical trials?
What is Aligos' financial strategy?
Where is Aligos Therapeutics headquartered?
